Copeptin and mid-regional pro-atrial natriuretic peptide in women with suspected or confirmed pre-eclampsia: comparison with sFlt-1/PlGF ratio
| Autor: | M M Alblas van der Meer, W. Visser, Langeza Saleh, S A A van den Berg, Ahj Danser, Rugina I. Neuman, A. H. Van Den Meiracker |
|---|---|
| Přispěvatelé: | Internal Medicine, Obstetrics & Gynecology, Public Health, Clinical Chemistry |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Gestational Age Gastroenterology Preeclampsia Copeptin Atrial natriuretic peptide Pre-Eclampsia Predictive Value of Tests Pregnancy Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Prospective cohort study Placenta Growth Factor Retrospective Studies Proteinuria Eclampsia Vascular Endothelial Growth Factor Receptor-1 Radiological and Ultrasound Technology business.industry Glycopeptides Obstetrics and Gynecology Gestational age General Medicine medicine.disease Reproductive Medicine embryonic structures Hypertensive disease of pregnancy Female medicine.symptom business Atrial Natriuretic Factor Biomarkers Maternal Serum Screening Tests |
| Zdroj: | Ultrasound in Obstetrics and Gynecology, 56(6), 872-878. John Wiley & Sons Ltd. |
| ISSN: | 0960-7692 |
| Popis: | OBJECTIVES Arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) may contribute to the pathogenesis of pre-eclampsia (PE), but their role remains to be elucidated. Our aims were to evaluate the surrogates of AVP and ANP, C-terminal pro-AVP (copeptin) and mid-regional pro-ANP (MR-proANP), as biomarkers for the prediction of PE-related pregnancy complications and whether they are associated with angiogenic markers and/or clinical manifestations of PE. METHODS This was a retrospective analysis of a prospective cohort study that enrolled pregnant women with suspected or confirmed PE, between December 2013 and April 2016. From each patient, a blood sample was obtained at study entry and serum levels of copeptin, MR-proANP, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured. We evaluated the ability of sFlt-1, PlGF, sFlt-1/PlGF ratio, copeptin and MR-proANP, assessed either alone or combined with traditional predictors (gestational age, parity, diastolic blood pressure and proteinuria), to predict maternal complications and fetal/neonatal complications. Models were compared using concordance statistic (C-index). RESULTS A total of 526 women were evaluated in the study. Women with confirmed PE displayed elevated serum copeptin and MR-proANP levels in comparison to those with suspected PE but no hypertensive disease of pregnancy. When combined with traditional predictors, the sFlt-1/PlGF ratio displayed a higher C-index than copeptin and MR-proANP (0.76, 0.63 and 0.67, respectively, vs 0.60 for the traditional predictors alone) for the prediction of maternal complications. Similarly, for the prediction of fetal/neonatal complications, the sFlt-1/PlGF ratio displayed a higher C-index than copeptin and MR-proANP when added to the traditional model (0.83, 0.79 and 0.80, respectively, vs 0.79 for the traditional predictors alone). When subdividing women according to sFlt-1/PlGF ratio (≥ 85 vs |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text